glp-1 news september 2025 Who Gets the Shot? Access by State Side Effects: Endocrine Society Journals

Costanza Alciati, a pharma analyst at GlobalData, told BioSpace in an email that GLP-1s will definitely dominate the market in the near future, but new entrants into the space are already looking for the next drug class that could revolutionize the space. Companies taking an alternative approach are forecast to capture only a very small portion of the obesity marketroughly 6.3%across the seven major markets (U.S., France, Germany, Italy, Spain, UK and Japan) by the end of 2031, according to Sara Reci, a senior analyst at GlobalData

Why BPC-157 and similar peptides are not legal to sell in Canada Direct answer: BPC-157 and comparable peptides have never been assessed or authorized by Health Canada, so they have no DIN and no market authorization

Mitteilung: Klinische Anwendungen der ditetisch-hormonalen Krebsbeeinflussung (Entzuckerungsmethode)

Made in a facility that also handles Milk, Soy, Egg, Gluten and products thereof